Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 794-797

  Demeter, L M ^a,g   Shafer, R W ^b   Meehan, P M ^c   Holden Wiltse, J ^c   Fischl, M A ^d   Freimuth, W W ^e   Para, M F ^f   Reichman, R C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e PFIZER INC   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONONUCLEAR CELL; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS ISOLATION; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; DELAVIRDINE; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0034002944     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.794-797.2000     Document Type: Article

References (19)

1. Byrnes, V. W., V. V. Sardana, W. A. Schleif, J. H. Condra, J. A. Waterbury, J. A. Wolfgang, W. J. Long, C. L. Schneider, A. J. Schlabach, B. S. Wolanski, et al. 1993. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1576-1579.
2. de Clercq, E. 1996. Non-nucleoside reverse transcriptase inhibitors (NNR-TIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:125-157.
3. Demeter, L. M., P. M. Meehan, G. Morse, P. Gerondelis, A. Dexter, L. Berrios, S. Cox, W. Freimuth, and R. C. Reichman. 1997. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14:136-144.
4. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, et al. 1993. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antirnicrob. Agents Chemother. 37:1127-1131.
5. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
6. Esnouf, R. M., J. Ren, A. L. Hopkins, C. K. Ross, E. Y. Jones, D. K. Stammers, and D. I. Stuart. 1997. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. USA 94:3984-3989.
7. Gerondelis, P., R. H. Archer, C. Palaniappan, R. C. Reichman, P. J. Fay, R. A. Bambara, and L. M. Demeter. 1999. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J. Virol. 73:5803-5813.
8. Hollinger, F. B., J. W. Bremer, L. E. Myers, J. W. M. Gold, L. McQuay, and the NIH/NIAID/DAIDS/ACTG Virology Laboratories. 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J. Clin. Microbiol. 30:1787-1794.
9. Japour, A. J., S. A. Fiscus, J. M. Arduino, D. L. Mayers, P. S. Reichelderfer, and D. R. Kuritzkes. 1994. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J. Clin. Microbiol. 32:2291-2294.
10. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
11. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
12. Nunberg, J. H., W. A. Schlief, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
13. Para, M. F., P. Meehan, J. Holden-Wiltse, M. Fischl, G. Morse, R. Shafer, L. M. Demeter, K. Wood, T. Nevin, N. Virani-Ketter, and W. W. Freimuth for the AIDS Clinical Group Protocol 260 Team. 1999. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. Antimicrob. Agents Chemother. 43: 1373-1378.
14. Richman, D., C.-K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
15. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, et al. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1560-1666.
16. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Shlief, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, K. W. Anderson, F. E. Massari, G. M. Shaw, and the L697,661 Working Group. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
17. Shafer, R. W., J. A. Eisen, T. C. Merigan, and D. A. Katzenstein. 1997. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J. Virol. 71:5441-5448.
18. Spence, R. A., W. M. Kati, K. S. Anderson, and K. A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
19. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, et al. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.